New Approaches to Patient Recruitment and Retention Anticipate Structural Change in the Clinical Research Enterprise, Tufts Center for the Study of Drug Development Reports
BOSTON – Jan. 26, 2016 – Responding to strong and growing pressures to accelerate the pace at which new medicines are launched, drug developers are innovating clinical study volunteer recruitment and retention to significantly improve clinical trial performance and efficiency, according to R&D leaders participating in a roundtable recently hosted by the Tufts Center for the Study of Drug Development.
Some of those new approaches include using Big Data to identify and understand patient populations, engaging the “voice of the patient” in trial design, and using new technologies and social media to reach, attract, and keep patients.
“The need to improve patient enrollment and retention rates is urgent and becoming more so, especially as we enter the era of stratified and precision medicines, in which investigative sites will need to recruit volunteers from more narrowly defined, and therefore more limited, sub-populations,” said Ken Getz, associate professor and director of sponsored research at Tufts CSDD.
Underscoring the critical need to improve recruitment and retention for increasingly complex clinical trials, he noted, is low awareness and over saturation among patients and health care providers, which have rendered traditional recruitment methods, such as advertising, less effective.
Other points made at the Tufts CSDD Executive Forum, summarized in the January Tufts CSDD R&D Management Report, released today, include the following:
Patient-centric study teams are using real-time data to understand and adjust the patient recruitment process as it unfolds.
More could and should be done to improve outreach to referring physicians, a primary conduit to clinical trial patients, as 82% of physicians say they’d be more willing to refer patients if they developed a working relationship with a clinical trial investigator.
Social media, which already supports communication within patient communities, will grow as a recruitment tool by providing new pathways between sites and specific population groups.
Comprehensive electronic medical records (EMRs) and health files will play a major role in patient recruitment within five years, but, for now, much of the relevant data do not exist in EMRs, and what does exist is difficult to search across files.
To purchase a single report or subscription, please visit our website.
FDA Grants Priority Review to Merck’s sBLA for Winrevair After Early Success in ZENITH PAH Trial
July 2nd 2025Merck’s bid to update Winrevair’s label advances with FDA priority review, backed by Phase III ZENITH data showing a 76% reduction in major morbidity and mortality events in patients with pulmonary arterial hypertension.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Phase III PROMINENT Trial Initiated to Evaluate Felzartamab for Primary Membranous Nephropathy
June 30th 2025The global Phase III PROMINENT trial has begun dosing patients to evaluate felzartamab in treating primary membranous nephropathy, a serious autoimmune kidney disorder with no FDA-approved therapies.
Putting Collective Insights Into Action to Advance Cancer Care: Key Examples From ASCO 2025
June 27th 2025At ASCO 2025, clinical operations leaders gained critical insights into how AI tools, bispecific antibodies, and evolving treatment paradigms are reshaping trial design, endpoint selection, and patient stratification.